1. Ulipristal acetate shows promise for treatment of PMDD
- Author
-
Comasco E., Kallner, H.K., and Bixo, M.
- Subjects
Progesterone -- Research ,Depression, Mental -- Research -- Drug therapy ,Ulipristal acetate -- Research ,Pharmaceuticals and cosmetics industries ,Health ,Psychology and mental health - Abstract
* Ninety-five women with premenstrual dysphoric disorder (PMDD) were randomized to ulipristal acetate 5 mg/day or placebo for three 28-day treatment cycles in a proof-of-concept study. * The ulipristal acetate group experienced greater mean improvement in scores on the Daily Record of Severity of Problems (DRSP), as well as on DRSP subscales measuring depressive and anger/irritability symptoms, compared with placebo. * Ulipristal acetate did not improve physical symptoms of PMDD relative to placebo., Women with premenstrual dysphoric disorder (PMDD) who received ulipristal acetate in a placebo-controlled trial experienced improvement on a range of symptoms that included irritability and depression. Half of the participants [...]
- Published
- 2021
- Full Text
- View/download PDF